Jane Street’s DiaMedica Therapeutics DMAC Stock Holding History

Jane Street’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57,546	Closed	-$395K	–	11369
2025 Q3	$395K	Buy	+57,546	New	+$312K	﹤0.01%	8346
2025 Q2	–	Sell	-100,669	Closed	-$382K	–	9859
2025 Q1	$382K	Buy	100,669 +58,457	+138%	+$334K	﹤0.01%	7379
2024 Q4	$229K	Buy	+42,212	New	+$199K	﹤0.01%	8179
2024 Q3	–	Sell	-15,091	Closed	-$44.5K	–	9708
2024 Q2	$44.5K	Sell	15,091 -147	-1%	-$403	﹤0.01%	8941
2024 Q1	$42.2K	Sell	15,238 -8,523	-36%	-$24.7K	﹤0.01%	8783
2023 Q4	$67.5K	Buy	+23,761	New	+$58.8K	﹤0.01%	8699
2023 Q1	–	Sell	-20,840	Closed	-$32.9K	–	9195
2022 Q4	$32.9K	Buy	20,840 +10,837	+108%	+$14.6K	﹤0.01%	8477
2022 Q3	$12K	Buy	+10,003	New	+$15.6K	﹤0.01%	9309
2021 Q1	–	Sell	-12,537	Closed	-$127K	–	9167
2020 Q4	$127K	Buy	+12,537	New	+$68.6K	﹤0.01%	7129

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Jane Street's DMAC Position: Q4 2025 in Review

Jane Street sold out of DiaMedica Therapeutics (DMAC) in Q4 2025, closing a stake of 57,546 shares — an estimated $395K sold.

Jane Street first reported a position in DMAC in Q4 2020 and held it in 9 quarters. The position peaked at $395K in Q3 2025. 92 funds tracked by Wall St. Rank hold DMAC as of Q4 2025.

Jane Street reported no remaining DiaMedica Therapeutics position as of Q4 2025 after selling out during the quarter.
Jane Street sold 57,546 DiaMedica Therapeutics shares in Q4 2025, an estimated $395K.
Jane Street first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 9 quarters.
Jane Street's DiaMedica Therapeutics position peaked at $395K in Q3 2025.
92 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.